Psychiatry & Neurology Doctors in Agana Heights, GU Accepting Medicare

2 Psychiatry & Neurology doctors found. Showing 1 - 2

Dr. Marvin Joseph Weniger Jr., MD Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: Bldg #50, Farenholt Ave., Agana Heights, GU 96910 Phone: 671-344-9401

Dr. Joan H Gill, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: Veterans Clinic, Usnh, Building E - 200, Agana Heights, GU 96919 Phone: 671-344-9200    Fax: 671-472-7249

News Archive

University of Sheffield's ScHARR team develops new index to measure hospital mortality rates

A team from the University of Sheffield's School of Health and Related Research (ScHARR) has developed a new index to measure hospital mortality rates that has been accepted for use by the Department of Health.

Study: Patients' abilities to see preferred GP have fallen greater in English practices

A new study published by the British Journal of General Practice has found that patients' abilities to see their preferred GP has fallen greater in English practices that have expanded, compared with those that stayed about the same size.

Medical Centers should follow Stanford's lead in banning gifts from drug companies

Stanford University Medical Center's decision to prohibit physicians from accepting any gifts from pharmaceutical sales representatives is "an austere measure that other medical centers should follow," a Los Angeles Times editorial states.

High family medical bills appear to reduce use of expensive medications: Study

People with rheumatoid arthritis whose health insurance requires them to pay a higher share of the cost are less likely to use biotech drugs than those with coverage that is more generous. High family medical bills also appear to reduce the use of these powerful but expensive medications, according to a new study in Health Services Research.

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.

Read more Medical News

› Verified 8 days ago